Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews · Eyes and Vision

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Adverse events · thyroid‐associated ophthalmopathy

Summary of findings table ‐ Rituximab showed no clear difference in adverse events compared with intravenous methylprednisolone (low certainty).

1 finding from 1 review

Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
RR 1.39 [0.9, 2.13]
1 study · 31 participants
Low